OUR TEAM
At Volastra, we are relentlessly committed to harnessing cutting-edge science to discover, develop and deliver novel therapies to patients. Our leadership team brings together expertise from diverse disciplines including drug discovery, clinical development, and business strategy. We are united by a shared passion to accelerate the pace of each new discovery, bridging the gap between scientific advancements and patient impact.
SANDI PETERSON, CHAIR
Operating PartnerClayton, Dubilier & Rice
David P. Southwell, MBA
Chief Executive OfficerVolastra Therapeutics
SAMUEL BAKHOUM, M.D., PH.D.
Co-Founder & Chief Scientific OfficerVolastra Therapeutics
Ellie McGuire
PartnerPolaris Partners
Arjun Balar, M.D.
SVP, Global Clinical DevelopmentLilly
Luc Dochez
Managing PartnerDROIA Ventures
JILL GOLDSTEIN, PH.D.
Senior Associate Vida Ventures
David Nicholson, PH.D.
Independent Board MemberFormer EVP & Chief R&D Officer, Allergan
Lewis Cantley, Ph.D.
Founder and Chair of Scientific Advisory Committee Professor Of Cell Medicine And Faculty Member, Dana Farber Cancer Center
Olivier Elemento, PH.D.
Founder and Scientific AdvisorDirector Of Englander Institute For Precision Medicine, Weill Cornell Medicine
Duane Compton, PH.D.
Scientific Advisor Dean, Geisel School Of Medicine, Dartmouth College
David Pellman, M.D.
Scientific Advisor Margaret M. Dyson Professor Of Pediatric Oncology, Dana-Farber Cancer Institute
Karen Vousden, Ph.D.
Scientific Advisor Chief Scientist, Cancer Research UK
Nicholas A. Saccomano, Ph.D.
Strategic AdvisorPresident & CEO, OnKure Inc
Charles Hugh-Jones, M.D., FRCP
Strategic AdvisorFormer CEO, Volastra Therapeutics